Patents by Inventor Wei-meng Zhao

Wei-meng Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20230242650
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: March 10, 2023
    Publication date: August 3, 2023
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20200347141
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: May 5, 2020
    Publication date: November 5, 2020
    Applicant: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Monoclonal antibodies to fibroblast growth factor receptor 2
    Patent number: 10689448
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: June 23, 2020
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20190153105
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: October 18, 2018
    Publication date: May 23, 2019
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Monoclonal antibodies to fibroblast growth factor receptor 2
    Patent number: 10138301
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: November 27, 2018
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20180094063
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: August 10, 2017
    Publication date: April 5, 2018
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Methods of detecting a tumor expressing fibroblast growth factor receptor 2
    Patent number: 9834609
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: December 5, 2017
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20160362496
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 15, 2016
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Monoclonal antibodies to fibroblast growth factor receptor 2
    Patent number: 9382324
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: July 5, 2016
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20140193899
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: November 4, 2013
    Publication date: July 10, 2014
    Applicant: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Monoclonal antibodies to fibroblast growth factor receptor 2
    Patent number: 8603987
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: December 10, 2013
    Assignee: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20120134994
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 31, 2012
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Monoclonal antibodies to fibroblast growth factor receptor 2
    Patent number: 8101723
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: January 24, 2012
    Assignee: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20100196364
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: November 6, 2009
    Publication date: August 5, 2010
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez